FrancophonIA/ELRC3.0 huggingface dataset:
English: Rifampicin (600 mg once daily) + velpatasvir (100 mg single dose)f
Estonian: Rifampitsiin (600 mg üks kord ööpäevas) + velpatasviir (100 mg ühekordne annus)f
English: Rifampicin (600 mg single dose) + velpatasvir (100 mg single dose)f
Estonian: Rifampitsiin (600 mg ühekordne annus) + velpatasviir (100 mg ühekordne annus)f
English: Rifampicin (600 mg once daily) + voxilaprevir (100 mg single dose)f
Estonian: Rifampitsiin (600 mg üks kord ööpäevas) + voksilapreviir (100 mg ühekordne annus)f
English: After a single 100 mg dose of [14C]-velpatasvir in healthy subjects, the blood to plasma ratio of [14C]-radioactivity ranged between 0.5 and 0.7.
Estonian: velpatasviiri annuse manustamist tervetele osalejatele oli [14C]-radioaktiivsuse vere/plasma suhe vahemikus 0,5…0,7.
English: Omeprazole (20 mg once daily) + sofosbuvir/velpatasvir/ voxilaprevir (400/100/ 100 mg single dose)c
Estonian: Omeprasool (20 mg üks kord ööpäevas) + sofosbuviir/velpatasviir/ voksilapreviir (400/100/100 mg ühekordne annus)c
English: No dose adjustment of Vosevi is required for patients with mild hepatic impairment (CPT Class A).
Estonian: Kerge maksafunktsiooni häirega patsientidel (CPT klass A) ei ole vaja Vosevi annust kohandada.
English: Outcome for patients without SVR Ontreatment virologic failurec
Estonian: Tulemused ilma SVR-ta patsientidel Raviaegne viroloogilise ravivastuse puudumine 0/411 Retsidiivd
English: Rifampicin (600 mg single dose) + voxilaprevir (100 mg single dose)f
Estonian: Rifampitsiin (600 mg ühekordne annus) + voksilapreviir (100 mg ühekordne annus)f
English: Co-administration of Vosevi with ciclosporin is not recommended (see section 4.4).
Estonian: Vosevi ja tsüklosporiini koosmanustamine ei ole soovitatav (vt lõik 4.4).
English: In vitro potential for sofosbuvir/velpatasvir/voxilaprevir drug-drug interactions
Estonian: In vitro katsetel põhinev sofosbuviiri/velpatasviiri/ voksilapreviiri koostoimepotentsiaal
English: Body weight
Estonian: • peavalu
English: Voxilaprevir
Estonian: Voksilapreviir
English: tenofovir disoproxil fumarate (600/200/300 mg once daily)g + sofosbuvir/
Estonian: Efavirens/emtritsitabiin/tenofoviir disoproksiilfumaraat (600/200/300 mg üks kord ööpäevas)g
English: Unchanged voxilaprevir is the major species present in faeces.
Estonian: Väljaheites esineb voksilapreviir suures osas muutumatul kujul.
English: • rifapentine (an antibiotic used to treat infections, including tuberculosis);
Estonian: • amiodaroon, mida kasutatakse südame rütmihäirete ravis; • rifapentiin (antibiootikum, mida kasutatakse infektsioonide, sh tuberkuloosi ravis);
English: ↔ Lopinavir ↔ Sofosbuvir ↔ Velpatasvir ↑ Voxilaprevir
Estonian: ↔ Modafiniil ↓ Sofosbuviir ↓ Velpatasviir ↓ Voksilapreviir
English: No dose adjustment of Vosevi, darunavir (ritonavir boosted) or emtricitabine/tenofovir disoproxil fumarate is required.
Estonian: Vosevi, (ritonaviiri abil võimendatud) darunaviiri ega emtritsitabiini/tenofoviirdisoproksiilfumaraadi annuseid ei ole vaja kohandada.
English: Vosevi is contraindicated with rifampicin (see section 4.3).
Estonian: Vosevi on vastunäidustatud rifampitsiiniga (vt lõik 4.3).
English: ↔ Sofosbuvir ↓ Velpatasvir ↔ Voxilaprevir
Estonian: ↓ Sofosbuviir ↓ Velpatasviir ↓ Voksilapreviir
English: ↔ Sofosbuvir ↔ Velpatasvir ↔ Voxilaprevir
Estonian: ↔ Sofosbuviir ↔ Velpatasviir ↔ Voksilapreviir
English: 1.6-fold↑ 2.1-fold↑ 2.7-fold↑ 1.3-fold↑ 1.6-fold↑ ~2-fold↑ 1.8-fold↑ GS-331007 1.6-fold↑ 1.9-fold↑ 5.5-fold↑ ≥10-fold↑ ≥20-fold↑ ~7-fold↑ 18-fold↑
Estonian: Sofosbuviir kordne↑ 2,1-kordne↑ 2,7-kordne↑ 1,3kordne↑
English: Pravastatin (40 mg single dose) + sofosbuvir/ velpatasvir/voxilaprevir (400/100/100 mg once daily) + voxilaprevir (100 mg once daily)f
Estonian: Pravastatiin (40 mg ühekordne annus) sofosbuviir/velpatasviir/voksilapreviir (400/100/100 mg üks kord ööpäevas) + voksilapreviir (100 mg üks kord ööpäevas)f (OATP1B inhibeerimine)
English: No clinically relevant pharmacokinetic differences due to race or gender have been identified for sofosbuvir, GS-331007, velpatasvir or voxilaprevir.
Estonian: Sofosbuviiri, GS-331007, velpatasviiri ega voksilapreviiri puhul ei täheldatud rassist ega soost sõltuvaid kliiniliselt olulisi farmakokineetilisi erinevusi.
English: e. Other includes patients with missing data and those who discontinued treatment prior to virologic suppression.
Estonian: e. Muud sisaldavad puuduvate andmetega patsiente ja neid, kes katkestasid ravi enne viroloogilist supressiooni.
English: a. The denominator for relapse is the number of patients with HCV RNA < LLOQ at their last on-treatment assessment.
Estonian: a. Retsidiiv määratletakse patsientide arvu põhjal, kelle HCV RNA on viimase raviaegse hinnangu ajal < LLOQ.
English: c. Other includes patients with missing data and those who discontinued treatment prior to virologic suppression.
Estonian: c. Muud sisaldavad puuduvate andmetega patsiente ja neid, kes katkestasid ravi enne viroloogilist supressiooni.
English: c. The denominator for relapse is the number of patients with HCV RNA <LLOQ at their last on-treatment assessment.
Estonian: c. Retsidiiv määratletakse patsientide arvu põhjal, kelle HCV RNA on viimase raviaegse hinnangu ajal < LLOQ.
English: Vosevi is contraindicated with carbamazepine (see section 4.3).
Estonian: Vosevi on vastunäidustatud koos karbamasepiiniga (vt lõik 4.3).
English: b. The denominator for relapse is the number of patients with HCV RNA < LLOQ at their last on-treatment assessment.
Estonian: b. Retsidiiv määratletakse patsientide arvu põhjal, kelle HCV RNA on viimase raviaegse hinnangu ajal < LLOQ.
English: b. Other includes patients with missing data and those who discontinued treatment prior to virologic suppression.
Estonian: b. Muud sisaldavad puuduvate andmetega patsiente ja neid, kes katkestasid ravi enne viroloogilist supressiooni.
English: d. The denominator for relapse is the number of patients with HCV RNA < LLOQ at their last on-treatment assessment.
Estonian: d. Retsidiiv määratletakse patsientide arvu põhjal, kelle HCV RNA on viimase raviaegse hinnangu ajal < LLOQ.
English: d. Other includes patients with missing data and those who discontinued treatment prior to virologic suppression.
Estonian: d. Muud sisaldavad puuduvate andmetega patsiente ja neid, kes katkestasid ravi enne viroloogilist supressiooni.
English: In the sofosbuvir/velpatasvir 12-week treatment group, a total of 3 of 440 (1%) patients (2 with genotype 1, 1 with genotype 4) qualified for resistance analysis due to relapse.
Estonian: Mitte ühelgi neist 21 patsiendist ei tekkinud ebaõnnestumisel NS3 ja NS5B NI RAV-e. Sofosbuviiri/velpatasviiri 12-nädalasest ravirühmast kvalifitseerus resistentsuse analüüsimiseks 440 patsiendist 3 (1%) (2 genotüübiga 1, 1 genotüübiga 4), kuna neil tekkis retsidiiv.
English: ≥50 and mL/min/1.
Estonian: (eGFR ≥30 ja mk/min/1,73 m2)
English: Interaction only studied with sofosbuvir/velpatasvir Expected:
Estonian: Koostoimeid on uuritud ainult sofosbuviiri/velpatasviiriga.
English: Very common side effects
Estonian: Sageli esinevad kõrvaltoimed
English: This means that, although there is insufficient evidence from clinical trials, the effectiveness of these herbal medicines is plausible and there is evidence that they have been used safely in this way for at least 30 years (including at least 15 years within the EU).
Estonian: See tähendab, et kuigi puuduvad kliinilistest uuringutest saadud piisavad tõendid, on tõenäoline, et need taimsed ravimid on tõhusad, ja on tõendeid, et neid on sel viisil ohutult kasutatud vähemalt 30 aastat (sh vähemalt 15 aastat ELis).
English: In its assessment, the HMPC also considered a few available clinical studies, including a study in patients suffering from sleep disorders, which suggested a positive effect on sleep.
Estonian: Oma hinnangus arvestas taimsete ravimite komitee ka väheste olemasolevate kliiniliste uuringute andmeid, sealhulgas unehäirete all kannatavate patsientide uuringut, millest nähtus uinumist soodustav mõju.
English: The plant is cultivated or gathered when flowering to obtain the above-ground parts for medicinal use.
Estonian: Taime kasvatatakse või korjatakse õitsemise ajal, et koguda selle maapealseid osi meditsiiniliseks kasutuseks.
English: At the time of the HMPC assessment, no side effects had been reported with these medicines.
Estonian: Taimsete ravimite komitee hindamise ajaks ei olnud teateid nende ravimite kõrvaltoimetest.
English: California poppy preparations should only be used in adults.
Estonian: Läänemagunaürdi valmistisi tohivad kasutada üksnes täiskasvanud.
English: California poppy EMA/HMPC/334023/2015
Estonian: Läänemagunaürt EMA/HMPC/334023/2015
English: Further information on the risks associated with California poppy medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Estonian: Lisateave läänemagunaürti sisaldava ravimiga kaasnevate riskide, sh selle ohutu kasutamise ettevaatusabinõude kohta, on ravimtaime monograafias Euroopa Ravimiameti veebilehe jaotises „All documents”: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Further information on the HMPC assessment of California poppy medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Estonian: Lisateave läänemagunaürti sisaldava ravimi hinnangu kohta, sh komitee kokkuvõtte detailne kirjeldus, on Euroopa Ravimiameti veebilehe jaotises „All documents”: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: The HMPC conclusions on the use of California poppy medicines to relieve mild symptoms of mental stress and to aid sleep are based on their ‘traditional use'.
Estonian: Taimsete ravimite komitee järeldused läänemagunaürti sisaldavate ravimite kasutamise kohta vaimse stressi kergete sümptomite leevendamisel ja uinumise soodustamisel põhineb nende traditsioonilisel kasutusel.
English: Any applications for the licensing of medicines containing California poppy have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Estonian: Läänemagunaürti sisaldava ravimi müügiloa taotlus tuleb esitada riiklikule ravimiametile, mis hindab taimse ravimi müügiloa taotlust, võttes arvesse taimsete ravimite komitee teaduslike järelduste kokkuvõtet.
English: California poppy is the common name for the above-ground parts of the plant Eschscholzia californica Cham.
Estonian: Läänemagunaürt on taime Eschscholzia californica Cham.
English: California poppy preparations are obtained by powdering the dried above-ground parts of the plant.
Estonian: Läänemagunaürdi valmistised saadakse taime maapealsete kuivatatud osade pulbristamisel.
English: This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of California poppy.
Estonian: See on taimsete ravimite komitee teaduslike järelduste kokkuvõte, mis käsitleb läänemagunaürdi meditsiinilisi kasutusviise.
English: What evidence supports the use of California poppy medicines?
Estonian: Millised tõendid toetavad läänemagunaürti sisaldava ravimi kasutamist?
English: The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing California poppy.
Estonian: ELi liikmesriigid võtavad taimsete ravimite komitee järeldusi arvesse, kui nad hindavad läänemagunaürti sisaldavate taimsete ravimite müügilubade taotlusi.
English: Herbal medicines containing California poppy are usually available in solid forms to be taken by mouth.
Estonian: Läänemagunaürti sisaldavaid taimseid ravimeid turustatakse tavaliselt suukaudsete tahkete ravimvormidena.
English: The HMPC concluded that, on the basis of its long-standing use, California poppy can be used for the relief of mild symptoms of mental stress and to aid sleep.
Estonian: Taimsete ravimite komitee järeldas, et pikaajalise kasutamise põhjal võib läänemagunaürti kasutada kergete stressisümptomite leevendamiseks ja une parandamiseks.
English: For practical information about using California poppy medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Estonian: Kui vajate läänemagunaürti sisaldava ravimi kasutamise kohta praktilisi nõuandeid, lugege ravimi pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: What are the risks associated with California poppy medicines?
Estonian: Mis riskid kaasnevad läänemagunaürti sisaldava ravimiga?
English: For more information about treatment with California poppy medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Estonian: Kui vajate lisateavet läänemagunaürti sisaldava ravimi kasutamise kohta, lugege palun pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Other information about California poppy medicines
Estonian: Muu teave läänemagunaürti sisaldava ravimi kohta
English: Information on the use and licensing of California poppy medicines in EU Member States should be obtained from the relevant national authorities.
Estonian: ELi liikmesriikides saab teavet läänemagunaürti sisaldava ravimi kasutamise ja müügiloa kohta riiklikult ravimiametilt.
English: How are California poppy medicines approved in the EU?
Estonian: Kuidas antakse Euroopa Liidus läänemagunaürti sisaldavale ravimile müügiluba?
English: This summary is not intended to provide practical advice on how to use medicines containing California poppy.
Estonian: Kokkuvõttes ei anta läänemagunaürti sisaldava ravimi kasutamise kohta praktilisi nõuandeid.
English: The HMPC conclusions on the use of California poppy medicines are based on their long-standing use.
Estonian: Seetõttu põhinevad taimsete ravimite komitee järeldused läänemagunaürti sisaldavate ravimite kasutamise kohta nende pikaajalisel kasutamisel.
English: Detailed instruction on how to take California poppy medicines and who can use them can be found in the package leaflet that comes with the medicine.
Estonian: Ravimiga kaasas oleval pakendi infolehel on üksikasjalikud juhised, kuidas läänemagunaürti sisaldavaid ravimeid kasutada ja kellele need on ette nähtud.
English: What is California poppy?
Estonian: Mis on läänemagunaürt?
English: It should be taken consistently either with or without food.
Estonian: Seda tuleb võtta iga päev samal ajal, koos toiduga või ilma.
English: This risk can be managed with restrictions and regular liver monitoring and is considered acceptable given the seriousness of the conditions and the lack of treatments.
Estonian: Seda riski saab ohjata piirangutega ja maksatalitluse korrapärase jälgimisega ning seda peetakse vastuvõetavaks, arvestades nende seisundite raskust ja ravivõimaluste puudumist.
English: Further information on Epidyolex can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/epidyolex.
Estonian: Lisateave Epidyolexi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/epidyolex.
English: What measures are being taken to ensure the safe and effective use of Epidyolex?
Estonian: Mis meetmed võetakse, et tagada Epidyolexi ohutu ja efektiivne kasutamine?
English: Epidyolex (cannabidiol) EMA/428834/2019
Estonian: Epidyolex (kannabidiool) EMA/428834/2019
English: The European Medicines Agency therefore decided that Epidyolex's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Seetõttu otsustas Euroopa Ravimiamet, et Epidyolexi kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Further information on the orphan designations can be found on the European Medicines Agency's website: (Dravet syndrome: 15 October 2014; Lennox-Gastaut syndrome: 20 March 2017).
Estonian: Lisateave harvikravimiks nimetatud ravimi kohta on leitav Euroopa Ravimiameti veebilehel: (Dravet' sündroom: 15. oktoober 2014; Lennoxi-Gastaut' sündroom: 20. märts 2017).
English: Epidyolex (cannabidiol)
Estonian: Epidyolex (kannabidiool)
English: Depending on the individual response and how well the medicine is tolerated, the doctor may increase the dose gradually up to a maximum of 10 mg/kg twice a day.
Estonian: Sõltuvalt patsiendi ravivastusest ja ravimi talutavusest tohib arst annust järk-järgult suurendada maksimumannuseni 10 mg/kg kaks korda ööpäevas.
English: Doses are measured and given by mouth with a suitable syringe supplied with the medicine.
Estonian: Annuseid mõõdetakse ja manustatakse suu kaudu komplektis oleva sobiva süstlaga.
English: As for all medicines, data on the use of Epidyolex are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Epidyolexi kasutamise kohta pidevat järelevalvet.
English: The most common reason for stopping treatment was increased blood levels of liver enzymes (a sign of liver problems).
Estonian: Ravi katkestamise levinuim põhjus oli maksaensüümide suurenenud sisaldus veres (maksaprobleemide sümptom).
English: Side effects reported with Epidyolex are carefully evaluated and any necessary action taken to protect patients.
Estonian: Epidyolexi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Symptoms include multiple types of seizure (fits), abnormal electrical activity in the brain, learning disability and behavioural problems.
Estonian: Sümptomid on näiteks mitut liiki epilepsiahood, aju elektrilise aktiivsuse häired, õppimishäired ja käitumisprobleemid.
English: Other information about Epidyolex
Estonian: Muu teave Epidyolexi kohta
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Epidyolex have been included in the summary of product characteristics and the package leaflet.
Estonian: Epidyolexi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: What is Epidyolex and what is it used for?
Estonian: Mis on Epidyolex ja milleks seda kasutatakse?
English: Epidyolex is available as a liquid containing 100 mg cannabidiol per ml.
Estonian: Epidyolexit turustatakse vedelikuna, mis sisaldab kannabidiooli 100 mg/ml.
English: For more information about using Epidyolex, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Epidyolex kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: After one week, the dose should be increased to a maintenance dose of 5 mg/kg twice a day.
Estonian: Ühe nädala möödudes peab annust suurendama säilitusannuseni 5 mg/kg kaks korda ööpäevas.
English: The most common side effects with Epidyolex (which may affect more than 1 in 10 people) are somnolence (sleepiness), decreased appetite, diarrhoea, fever, tiredness and vomiting.
Estonian: Epidyolexi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on unisus, isutus, kõhulahtisus, palavik, väsimus ja oksendamine.
English: Epidyolex can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the treatment of epilepsy.
Estonian: Epidyolex on retseptiravim ning ravi peab alustama ja jälgima epilepsia ravis kogenud arst.
English: Why is Epidyolex authorised in the EU?
Estonian: Miks Epidyolex ELis heaks kiideti?
English: Although the way it works is not clearly understood, the active substance in Epidyolex, cannabidiol, is thought to act on targets that play a role in the movement of calcium in the cells.
Estonian: Ehkki ravimi toimemehhanism ei ole täielikult teada, oletatakse, et Epidyolexi toimeaine kannabidiool toimib sihtmärkidele, mis osalevad kaltsiumi liikumises rakkudes.
English: Epidyolex must not be used in patients whose blood levels of liver enzymes are more than three times the normal limit and who also have levels of bilirubin (another marker of liver problems) more than twice the normal limit.
Estonian: Epidyolexit ei tohi kasutada patsiendid, kellel on maksaensüümide sisaldus veres üle 3 korra normist suurem ja ka bilirubiini sisaldus (samuti maksaprobleemide marker) üle 2 korra normist suurem.
English: Four studies involving 715 patients with Lennox-Gastaut or Dravet syndrome looked at the effect of Epidyolex when added to treatment with other epilepsy medicines.
Estonian: Neljas uuringus, milles osales 715 Lennoxi-Gastaut' sündroomi või Dravet' sündroomiga patsienti, uuriti muude epilepsiaravimite lisaravimina kasutatud Epidyolexi toimet.
English: Regarding safety, treatment with Epidyolex is associated with an increased risk of liver problems.
Estonian: Ohutuse seisukohast kaasneb Epidyolexraviga maksaprobleemide tekke suurenenud risk.
English: Epidyolex contains the active substance cannabidiol.
Estonian: Epidyolex sisaldab toimeainena kannabidiooli.
English: They showed that Epidyolex lowered the number of seizures after 14 weeks in patients who were also taking clobazam.
Estonian: Uuringutes tõendati, et Epidyolex vähendas 14 nädala järel epilepsiahooge patsientidel, kes võtsid ka klobasaami.
English: The recommended starting dose is 2.5 mg per kilogram body weight given twice a day.
Estonian: Soovitatav algannus on 2,5 mg kehamassi kg kohta kaks korda ööpäevas.
English: Cannabidiol is also thought to act on adenosine, a chemical messenger in the brain that plays an important role in suppressing seizures.
Estonian: Kannabidiool mõjutab arvatavasti adenosiini, aju keemilist virgatsainet, millel on epilepsiahoogude pärssimisel oluline roll.
English: The main studies showed that Epidyolex is effective at lowering the number of seizures in patients with Lennox-Gastaut and Dravet syndromes who are taking clobazam.
Estonian: Põhiuuringutes tõendati, et Epidyolex vähendab efektiivselt epilepsiahoogude arvu Lennoxi-Gastaut' või Dravet' sündroomiga patsientidel, kes kasutavad klobasaami.
English: As this is important for the transmission of electrical signals in some nerve cells, and seizures are caused by excessive electrical activity in the brain, altering the movement of calcium is expected to reduce or prevent the
Estonian: Kuna see mõjutab elektriliste signaalide edastamist teatud närvirakkudes ning epilepsiahooge põhjustab aju liiga suur elektriline aktiivsus, aitab kaltsiumi liikumise muutmine eeldatavalt vähendada või ennetada epilepsiahooge Lennoxi-Gastaut' sündroomi või Dravet' sündroomiga patsientidel.
English: What are the risks associated with Epidyolex?
Estonian: Mis riskid Epidyolexiga kaasnevad?
English: How does Epidyolex work?
Estonian: Kuidas Epidyolex toimib?
English: For the full list of side effects of Epidyolex, see the package leaflet.
Estonian: Epidyolexi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: In the first two studies, patients with Lennox-Gastaut syndrome taking Epidyolex in combination with clobazam had a reduction of up to 64% in the number of drop seizures (brief loss of muscle tone and reduced consciousness, causing abrupt falls), compared with a reduction of up to 31% for patients given placebo (a dummy treatment) with clobazam.
Estonian: Esimeses kahes uuringus vähenes Lennoxi-Gastaut' sündroomiga patsientidel, kes said Epidyolexit koos klobasaamiga, atooniliste hoogude (lühiajaline lihastoonuse kadu ja teadvuse hägunemine, mis põhjustavad äkilist kukkumist) arv kuni 64% ning patsientidel, kes said platseebot (näiv ravim) koos klobasaamiga, kuni 31%.
English: An overview of Epidyolex and why it is authorised in the EU
Estonian: Ülevaade ravimist Epidyolex ja ELis müügiloa väljastamise põhjendus